Successful discontinuation of eculizumab therapy in a patient with aHUS

Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome

(2013) M. Frimat et al.   BLOOD

Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria

(2013) Peter Hillmen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

(2013) C.M. Legendre et al.   NEW ENGLAND JOURNAL OF MEDICINE

Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome

(2010) Hallie C. Prescott et al.   AMERICAN JOURNAL OF HEMATOLOGY

Eculizumab: Safety and Efficacy After 17 Months of Treatment in a Renal Transplant Patient With Recurrent Atypical Hemolytic-Uremic Syndrome: Case Report

(2010) V. Châtelet et al.   TRANSPLANTATION PROCEEDINGS

Maintenance of Kidney Function Following Treatment With Eculizumab and Discontinuation of Plasma Exchange After a Third Kidney Transplant for Atypical Hemolytic Uremic Syndrome Associated With a CFH Mutation

(2009) Jean-Claude Davin et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Eculizumab for paroxysmal nocturnal haemoglobinuria

(2009) Charles Parker   LANCET